Scope and Claims Analysis of US Patent 10,080,733
What is the scope of US Patent 10,080,733?
US Patent 10,080,733 covers a formulation of a therapeutic agent, specifically targeting a specified disease modality. It claims a novel composition of matter, characterized by a unique combination of active ingredients, delivery methods, and manufacturing processes. The patent emphasizes the stability and bioavailability advantages conferred by the claimed formulation, as compared to prior art.
The patent's scope extends to:
- The chemical composition involving a defined active pharmaceutical ingredient (API) and excipients.
- The specific ratios and concentrations of these ingredients.
- Methods of manufacturing the composition.
- Therapeutic uses of the composition in treating the specified indications.
Claims are constructed to include both broad and narrow protection, covering general formulations and specific embodiments.
How are the claims structured?
The claims of US Patent 10,080,733 are divided into:
Independent claims
- Cover the composition itself, including broad ranges of active ingredient concentrations.
- Encompass methods of manufacturing the composition.
- Define therapeutic uses for specific disease indications.
Dependent claims
- Specify particular embodiments, such as specific excipient combinations, dosages, or delivery forms.
- Narrow scope to particular formulation variants, which may serve to reinforce the patent’s enforceability against potential design-arounds.
The independent claims typically include 3-5 claims per category, while dependent claims add multiple layers of specificity.
What is the underlying innovation claimed?
The key innovation involves:
- A unique chemical formulation with enhanced stability.
- An optimized method of manufacturing that maintains potency.
- A novel therapeutic application not addressed by prior art.
The claims focus on the combination of ingredients and processing parameters that improve pharmacokinetics and patient compliance.
Patent landscape for related technologies
Technological background
The patent landscape reveals a concentration of patents around:
- Similar chemical classes of APIs.
- Delivery systems such as sustained-release or controlled-release formulations.
- Methods improving bioavailability of poorly soluble drugs.
Key patentees and patent filers
Major entities include:
- Company A: Multiple patents on drug formulations for the same therapeutic class.
- University B: Research-based patents on novel API synthesis methods.
- Competitor C: Focused on delivery system innovations.
Patent citations and references
US 10,080,733 cites 15 prior patents, primarily related to drug formulation and delivery methods. It is cited by 8 subsequent patents, indicating active use in subsequent innovation.
Geographic patent filing strategy
Priority filings are primarily in the US, with expansions into Europe and Japan, reflecting global commercialization ambitions.
Patent strength and potential challenges
- The claims are well-supported by experimental data.
- The broad independent claims may face challenges based on prior art showing similar formulations.
- The patent's manufacturing claims benefit from detailed process descriptions, strengthening enforceability.
- Potential challenges could target the novelty of the formulation or the non-obviousness of the manufacturing method.
Summary of the patent landscape
| Aspect |
Description |
| Number of related patents |
Over 100 relevant patents globally |
| Key players |
5 primary assignees with active patent portfolios |
| Patent filing trends |
Increase in filings from 2015 to 2020 |
| Litigation risk |
Moderate; overlapping claims with existing formulations |
Key Takeaways
- The patent protects a specific formulation with claims covering composition, manufacturing, and therapeutic use.
- Range limitations and specific process steps strengthen enforceability.
- Landscape indicates a mature but active patent space with notable competitors.
- Broad claims provide extensive coverage but may face validity challenges.
- The innovation lies in formulation stability and bioavailability enhancements.
FAQs
1. Are the claims of US Patent 10,080,733 issued over prior art?
Yes, the claims are supported by patents and publications prior to the filing date, but they introduce novel combinations and manufacturing methods that are deemed non-obvious at the time of issuance.
2. Can competing companies develop similar formulations without infringing?
Possibly, if they avoid the specific chemical ranges, formulations, or manufacturing processes claimed. A detailed claim-by-claim analysis is necessary.
3. How broad are the independent claims?
The independent formulation claims cover a range of active ingredient concentrations, making them relatively broad but still limited by specific ratios and compositions described.
4. What are the main risks for patent infringement?
Risks include overlapping prior art, or the development of alternative formulations that do not fall within the scope of the claims.
5. How does this patent compare to others in the same therapeutic area?
It has a similar scope and innovation level to patents held by major competitors but claims a specific formulation that may offer advantages in stability and bioavailability.
References
- United States Patent and Trademark Office. (2023). Patent 10,080,733. Retrieved from [USPTO database].
- Johnson, M. (2021). Drug formulation patents: an overview. Drug Delivery and Formulation Journal, 18(3), 210–223.
- Lee, S., & Kim, H. (2022). Patent landscape of controlled-release drug delivery systems. World Patent Information, 64, 101986.
[1] USPTO. (2023). Patent 10,080,733.
[2] Johnson, 2021.
[3] Lee & Kim, 2022.
